Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.

Joon Y ParkJonathan KingHoward ReberOscar Joe HinesMichael A MederosHanlin L WangDavid DawsonZev WainbergTimothy DonahueMark D Girgis

Published in: Journal of surgical oncology (2020)

In this large cohort of resected PDAC, routine SMAD4 assessment identified a subpopulation of patients with SMAD4(-) and histologically poorly differentiated tumors that had significantly poor prognosis with median OS of 8.6 months. Characterization of the role of SMAD4 within the context of poorly differentiated tumors may help settle the controversy regarding SMAD4 in PDAC and lead to identification of personalized therapeutic strategies for subgroups of PDAC.

Keyphrases

transforming growth factor
epithelial mesenchymal transition
poor prognosis
long non coding rna
end stage renal disease
prognostic factors
ejection fraction
chronic kidney disease
signaling pathway
lymph node